🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05402839
Recruiting Observational

Screening of Malignant Hyperthermia Susceptible Individuals

NCT05402839 · tracked via the Priya Life Science China tracker
Sponsor
Peking University Third Hospital
Phase
Observational
Started
2022-02-22
Last updated
2022-06-02

Condition(s) studied

Malignant Hyperthermia

Study summary

This study intends to target patients who underwent surgery under general anesthesia during the study period and developed malignant hyperthermia during or after surgery. Therefore, the total sample size was estimated to be about 50 people based on the past incidence of this rare disease. Every year, about 20 patients and their families who developed malignant hyperthermia during or after surgery will participate in this nationwide study (estimated by the current incidence of malignant hyperthermia), and about 1-5 patients will be admitted to Peking University Third Hospital participate in this research. Relevant specimens were collected from malignant hyperthermia (MH) patients and their family members for genetic analysis to determine the mutation of MH-related pathogenic gene loci.

Eligibility

Sex
ALL
Min age
0 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * Patients undergoing surgery under general anesthesia during the study period developed malignant hyperthermia during or after surgery. Exclusion Criteria: * Malignant hyperthermia was ruled out by later treatment and diagnosis; * The patient or family member refuses to be recruited.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking University Third Hospital Beijing Beijing Municipality Recruiting

More Peking University Third Hospital trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05402839 on ClinicalTrials.gov ↗ ← All trials in China